Type 2 diabetes occurs when the pancreatic beta cells fail to meet the increased insulin requirement in insulin-resistant individuals. A new therapeutic approach targeting glutamate receptors on beta cells improves insulin secretion and preserves beta cell mass.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Halban, P.A. et al. Diabetes Care 37, 1751–1758 (2014).
Marquard, J. et al. Nat. Med. 21, 363–372 (2015).
Maechler, P. & Wollheim, C.B. Nature 402, 685–689 (1999).
Feldmann, N. et al. Mol. Cell. Endocrinol. 338, 46–57 (2011).
Vetterli, L. et al. Mol. Biol. Cell 23, 3851–3862 (2012).
Gheni, G., et al.. Cell Rep. 9, 661–673 (2014).
Inagaki, N. et al. FASEB J. 9, 686–691 (1995).
Cabrera, O. et al. Cell Metab. 7, 545–554 (2008).
Hardingham, G.E. & Bading, H. Nat. Rev. Neurosci. 11, 682–696 (2010).
Dadi, P.K. et al. J. Biol. Chem. 289, 12435–12445 (2014).
Soleimanpour, S.A. et al. J. Biol. Chem. 285, 40050–40059 (2010).
Colella, M. et al. Proc. Natl. Acad. Sci. USA 105, 2859–2864 (2008).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wollheim, C., Maechler, P. Beta cell glutamate receptor antagonists: novel oral antidiabetic drugs?. Nat Med 21, 310–311 (2015). https://doi.org/10.1038/nm.3835
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3835